Michael R Hayden Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Michael R Hayden.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Michael R Hayden. Michael R Hayden is Director in IONIS PHARMACEUTICALS INC ($ISIS) and Director in Xenon Pharmaceuticals Inc. ($XENE) and Director in Aurinia Pharmaceuticals Inc. ($AUPH) and Director in AbCellera Biologics Inc. ($ABCL) and Director in 89bio, Inc. ($ETNB).
Latest Insider Trading Transactions of Michael R Hayden
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ETNB, ABCL, AUPH, ISIS, XENE
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Apr 19 2021 | ETNB | 89bio, Inc. | Hayden Michael R | Director | Option Exercise | A | 24.16 | 12,500 | 302,000 | 12,500 | |
Apr 19 2021 | ETNB | 89bio, Inc. | Hayden Michael R | Director | Option Exercise | A | 24.16 | 12,500 | 302,000 | 12,500 | |
Feb 25 2021 | ETNB | 89bio, Inc. | Hayden Michael R | Director | Option Exercise | M | 3.11 | 13,637 | 42,411 | 22,730 | |
Feb 25 2021 | ETNB | 89bio, Inc. | Hayden Michael R | Director | Option Exercise | M | 1.93 | 6,447 | 12,443 | 2,933 | |
Feb 25 2021 | ETNB | 89bio, Inc. | Hayden Michael R | Director | Option Exercise | M | 1.93 | 60,820 | 117,383 | 27,647 | |
Feb 25 2021 | ETNB | 89bio, Inc. | Hayden Michael R | Director | Buy | M | 3.11 | 13,637 | 42,411 | 80,904 | 67.3 K to 80.9 K (+20.27 %) |
Feb 25 2021 | ETNB | 89bio, Inc. | Hayden Michael R | Director | Buy | M | 1.93 | 6,447 | 12,443 | 67,267 | 60.8 K to 67.3 K (+10.60 %) |
Feb 25 2021 | ETNB | 89bio, Inc. | Hayden Michael R | Director | Buy | M | 1.93 | 60,820 | 117,383 | 60,820 | 0 to 60.8 K |
Feb 02 2021 | AUPH | Aurinia Pharmaceut ... | Hayden Michael R | Director | Option Exercise | M | 6.42 | 15,000 | 96,300 | 0 | |
Feb 02 2021 | AUPH | Aurinia Pharmaceut ... | Hayden Michael R | Director | Option Exercise | M | 6.06 | 30,000 | 181,800 | 0 | |
Feb 02 2021 | AUPH | Aurinia Pharmaceut ... | Hayden Michael R | Director | Option Exercise | M | 5.44 | 50,000 | 272,000 | 0 | |
Feb 02 2021 | AUPH | Aurinia Pharmaceut ... | Hayden Michael R | Director | Buy | M | 6.42 | 15,000 | 96,300 | 95,000 | 80 K to 95 K (+18.75 %) |
Feb 02 2021 | AUPH | Aurinia Pharmaceut ... | Hayden Michael R | Director | Buy | M | 6.06 | 30,000 | 181,800 | 80,000 | 50 K to 80 K (+60.00 %) |
Feb 02 2021 | AUPH | Aurinia Pharmaceut ... | Hayden Michael R | Director | Buy | M | 5.44 | 50,000 | 272,000 | 50,000 | 0 to 50 K |
Dec 17 2020 | ABCL | AbCellera Biologic ... | Hayden Michael R | Director | Option Exercise | A | 2.76 | 100,000 | 276,000 | 100,000 | |
Dec 17 2020 | ABCL | AbCellera Biologic ... | Hayden Michael R | Director | Option Exercise | M | 0.33 | 270,000 | 89,100 | 540,000 | |
Dec 17 2020 | ABCL | AbCellera Biologic ... | Hayden Michael R | Director | Buy | P | 20.00 | 73,665 | 1,473,300 | 118,245 | 44.6 K to 118.2 K (+165.24 %) |
Dec 17 2020 | ABCL | AbCellera Biologic ... | Hayden Michael R | Director | Buy | C | 0.00 | 117,647 | 0 | 1,103,397 | 985.8 K to 1.1 M (+11.93 %) |
Dec 17 2020 | ABCL | AbCellera Biologic ... | Hayden Michael R | Director | Buy | M | 0.33 | 270,000 | 89,100 | 985,750 | 715.8 K to 985.8 K (+37.72 %) |
Oct 19 2020 | ISIS | IONIS PHARMACEUTIC ... | Hayden Michael R | Director | Option Exercise | M | 0.00 | 1,778 | 0 | 3,554 | |
Oct 19 2020 | ISIS | IONIS PHARMACEUTIC ... | Hayden Michael R | Director | Buy | M | 0.00 | 1,778 | 0 | 5,334 | 3.6 K to 5.3 K (+50.00 %) |
Jul 14 2020 | ETNB | 89bio, Inc. | Hayden Michael R | Director | Option Exercise | A | 24.29 | 7,000 | 170,030 | 7,000 | |
Jul 06 2020 | ISIS | IONIS PHARMACEUTIC ... | Hayden Michael R | Director | Option Exercise | A | 60.20 | 12,000 | 722,400 | 12,000 | |
Jul 06 2020 | ISIS | IONIS PHARMACEUTIC ... | Hayden Michael R | Director | Option Exercise | A | 0.00 | 5,333 | 0 | 5,333 | |
Jul 06 2020 | ISIS | IONIS PHARMACEUTIC ... | Hayden Michael R | Director | Option Exercise | M | 0.00 | 1,778 | 0 | 5,332 | |
Jul 06 2020 | ISIS | IONIS PHARMACEUTIC ... | Hayden Michael R | Director | Buy | M | 0.00 | 1,778 | 0 | 3,556 | 1.8 K to 3.6 K (+100.00 %) |
Jun 02 2020 | XENE | Xenon Pharmaceutic ... | Hayden Michael R | Director | Option Exercise | A | 13.11 | 10,000 | 131,100 | 10,000 | |
Apr 07 2020 | ETNB | 89bio, Inc. | Hayden Michael R | Director | Option Exercise | A | 21.40 | 7,000 | 149,800 | 7,000 | |
Nov 13 2019 | ETNB | 89bio, Inc. | Hayden Michael R | Director | Option Exercise | C | 0.00 | 366,667 | 0 | 0 | |
Nov 13 2019 | ETNB | 89bio, Inc. | Hayden Michael R | Director | Buy | C | 0.00 | 58,978 | 0 | 77,728 | 18.8 K to 77.7 K (+314.55 %) |
Nov 13 2019 | ETNB | 89bio, Inc. | Hayden Michael R | Director | Option Exercise | C | 0.00 | 366,667 | 0 | 0 | |
Nov 13 2019 | ETNB | 89bio, Inc. | Hayden Michael R | Director | Buy | P | 16.00 | 18,750 | 300,000 | 18,750 | 0 to 18.8 K |
Nov 13 2019 | ETNB | 89bio, Inc. | Hayden Michael R | Director | Buy | C | 0.00 | 58,978 | 0 | 77,728 | 18.8 K to 77.7 K (+314.55 %) |
Nov 13 2019 | ETNB | 89bio, Inc. | Hayden Michael R | Director | Buy | P | 16.00 | 18,750 | 300,000 | 18,750 | 0 to 18.8 K |
Oct 17 2019 | ISIS | IONIS PHARMACEUTIC ... | Hayden Michael R | Director | Option Exercise | M | 0.00 | 1,778 | 0 | 5,332 | |
Oct 17 2019 | ISIS | IONIS PHARMACEUTIC ... | Hayden Michael R | Director | Buy | M | 0.00 | 1,778 | 0 | 1,778 | 0 to 1.8 K |
Sep 18 2019 | XENE | Xenon Pharmaceutic ... | Hayden Michael R | Director | Option Exercise | A | 9.44 | 15,000 | 141,600 | 15,000 | |
Jul 03 2019 | ISIS | IONIS PHARMACEUTIC ... | Hayden Michael R | Director | Option Exercise | A | 64.80 | 16,000 | 1,036,800 | 16,000 | |
Jul 03 2019 | ISIS | IONIS PHARMACEUTIC ... | Hayden Michael R | Director | Option Exercise | A | 0.00 | 7,110 | 0 | 7,110 | |
Mar 20 2019 | XENE | Xenon Pharmaceutic ... | Hayden Michael R | Director | Option Exercise | M | 3.38 | 20,576 | 69,547 | 0 | |
Mar 20 2019 | XENE | Xenon Pharmaceutic ... | Hayden Michael R | Director | Buy | M | 3.38 | 20,576 | 69,547 | 50,924 | 30.3 K to 50.9 K (+67.80 %) |
Mar 12 2019 | XENE | Xenon Pharmaceutic ... | Hayden Michael R | Director | Gift | G | 0.00 | 17,337 | 0 | 114,403 | 97.1 K to 114.4 K (+17.86 %) |
Mar 12 2019 | XENE | Xenon Pharmaceutic ... | Hayden Michael R | Director | Gift | G | 0.00 | 24,045 | 0 | 107,562 | 131.6 K to 107.6 K (-18.27 %) |
Oct 15 2018 | ISIS | IONIS PHARMACEUTIC ... | Hayden Michael R | Director | Option Exercise | A | 0.00 | 7,110 | 0 | 7,110 | |
Oct 15 2018 | ISIS | IONIS PHARMACEUTIC ... | Hayden Michael R | Director | Option Exercise | A | 0.00 | 7,110 | 0 | 7,110 | |
Sep 24 2018 | ISIS | IONIS PHARMACEUTIC ... | Hayden Michael R | Director | Option Exercise | A | 50.80 | 32,000 | 1,625,600 | 32,000 | |
Jun 05 2018 | XENE | Xenon Pharmaceutic ... | Hayden Michael R | Director | Option Exercise | A | 6.20 | 15,000 | 93,000 | 15,000 | |
Mar 01 2018 | XENE | Xenon Pharmaceutic ... | Hayden Michael R | Director | Gift | G | 0.00 | 21,180 | 0 | 97,066 | 75.9 K to 97.1 K (+27.91 %) |
Mar 01 2018 | XENE | Xenon Pharmaceutic ... | Hayden Michael R | Director | Gift | G | 0.00 | 29,580 | 0 | 131,607 | 161.2 K to 131.6 K (-18.35 %) |
Aug 14 2017 | XENE | Xenon Pharmaceutic ... | Hayden Michael R | Director | Buy | P | 2.75 | 15,000 | 41,247 | 161,187 | 146.2 K to 161.2 K (+10.26 %) |
Jun 02 2017 | XENE | Xenon Pharmaceutic ... | Hayden Michael R | Director | Option Exercise | A | 3.85 | 3,500 | 13,475 | 3,500 | |
Mar 15 2017 | XENE | Xenon Pharmaceutic ... | Hayden Michael R | Director | Option Exercise | M | 3.56 | 3,086 | 10,986 | 0 | |
Mar 15 2017 | XENE | Xenon Pharmaceutic ... | Hayden Michael R | Director | Option Exercise | M | 3.07 | 4,629 | 14,211 | 0 | |
Mar 15 2017 | XENE | Xenon Pharmaceutic ... | Hayden Michael R | Director | Option Exercise | M | 3.77 | 4,115 | 15,514 | 0 | |
Mar 15 2017 | XENE | Xenon Pharmaceutic ... | Hayden Michael R | Director | Option Exercise | M | 3.67 | 5,144 | 18,878 | 0 | |
Mar 15 2017 | XENE | Xenon Pharmaceutic ... | Hayden Michael R | Director | Option Exercise | M | 3.76 | 25,720 | 96,707 | 0 | |
Mar 15 2017 | XENE | Xenon Pharmaceutic ... | Hayden Michael R | Director | Option Exercise | M | 3.70 | 18,004 | 66,615 | 0 | |
Mar 15 2017 | XENE | Xenon Pharmaceutic ... | Hayden Michael R | Director | Buy | M | 3.56 | 3,086 | 10,986 | 30,348 | 27.3 K to 30.3 K (+11.32 %) |
Mar 15 2017 | XENE | Xenon Pharmaceutic ... | Hayden Michael R | Director | Buy | M | 3.07 | 4,629 | 14,211 | 27,262 | 22.6 K to 27.3 K (+20.45 %) |
Mar 15 2017 | XENE | Xenon Pharmaceutic ... | Hayden Michael R | Director | Buy | M | 3.77 | 4,115 | 15,514 | 22,633 | 18.5 K to 22.6 K (+22.22 %) |
Mar 15 2017 | XENE | Xenon Pharmaceutic ... | Hayden Michael R | Director | Buy | M | 3.67 | 5,144 | 18,878 | 146,187 | 141 K to 146.2 K (+3.65 %) |
Mar 15 2017 | XENE | Xenon Pharmaceutic ... | Hayden Michael R | Director | Buy | M | 3.76 | 25,720 | 96,707 | 141,043 | 115.3 K to 141 K (+22.30 %) |
Mar 15 2017 | XENE | Xenon Pharmaceutic ... | Hayden Michael R | Director | Buy | M | 3.70 | 18,004 | 66,615 | 115,323 | 97.3 K to 115.3 K (+18.50 %) |
Jun 03 2016 | XENE | Xenon Pharmaceutic ... | Hayden Michael R | Director | Option Exercise | A | 7.38 | 3,500 | 25,830 | 3,500 | |
May 27 2016 | XENE | Xenon Pharmaceutic ... | Hayden Michael R | Director | Option Exercise | M | 3.30 | 8,230 | 27,159 | 0 | |
May 27 2016 | XENE | Xenon Pharmaceutic ... | Hayden Michael R | Director | Buy | M | 3.30 | 8,230 | 27,159 | 18,518 | 10.3 K to 18.5 K (+80.00 %) |
May 06 2015 | XENE | Xenon Pharmaceutic ... | Hayden Michael R | Director | Option Exercise | A | 13.48 | 3,086 | 41,599 | 3,086 | |
Nov 12 2014 | XENE | Xenon Pharmaceutic ... | Hayden Michael R | Director | Option Exercise | C | 0.00 | 1,504 | 0 | 0 | |
Nov 12 2014 | XENE | Xenon Pharmaceutic ... | Hayden Michael R | Director | Option Exercise | C | 0.00 | 2,693 | 0 | 0 | |
Nov 12 2014 | XENE | Xenon Pharmaceutic ... | Hayden Michael R | Director | Option Exercise | C | 0.00 | 10,030 | 0 | 0 | |
Nov 12 2014 | XENE | Xenon Pharmaceutic ... | Hayden Michael R | Director | Buy | C | 0.00 | 1,504 | 0 | 75,886 | 74.4 K to 75.9 K (+2.02 %) |
Nov 12 2014 | XENE | Xenon Pharmaceutic ... | Hayden Michael R | Director | Buy | C | 0.00 | 2,693 | 0 | 74,382 | 71.7 K to 74.4 K (+3.76 %) |
Nov 12 2014 | XENE | Xenon Pharmaceutic ... | Hayden Michael R | Director | Buy | C | 0.00 | 10,030 | 0 | 71,689 | 61.7 K to 71.7 K (+16.27 %) |
Nov 06 2014 | XENE | Xenon Pharmaceutic ... | Hayden Michael R | Director | Option Exercise | A | 9.00 | 5,144 | 46,296 | 5,144 |
Page: 1